Abstract:The present study aimed to identify the therapeutic role of the forkhead box M1 (FOXM1)-associated pathway in triple-negative breast cancer (TNBC). Using a Cancer Landscapes-based analysis, a gene regulatory network model was constructed. The present results demonstrated that FOXM1 occupies a key position in gene networks and is a critical regulatory gene in breast cancer. Using breast carcinoma gene expression data from The Cancer Genome Atlas, it was identified that FOXM1 expression was increased in the basal-like breast cancer subtype compared with other breast cancer subtypes. RNA-sequencing analysis of MDA-MB-231 cells treated with 4 and 10 mu l/ml Thiostrepton identified 662 and 5,888 significantly differentially expressed genes, respectively. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses demonstrated that FOXM1 was highly associated with multiple biological processes and was markedly associated with metabolic pathways in TNBC. The use of Search Tool for the Retrieval of Interacting Genes/Proteins provided a critical assessment and integration of protein-protein interactions, and demonstrated the multiple important functions of FOXM1 in TNBC. Real-time cell analysis, reverse transcription-quantitative polymerase chain reaction and immunofluorescence staining were used to assess the anti-tumor activity of Thiostrepton in TNBC cells in vitro. The present results identified that suppression of FOXM1 using Thiostrepton inhibited MDA-MB-231 cell proliferation and the expression of cell cycle-associated genes, including cyclin A2, cyclin B2, checkpoint kinase 1, centrosomal protein 55 and polo like kinase 1. Immunofluorescence staining analysis demonstrated that vimentin, filamentous actin and zinc finger E-box-binding homeobox 1 were all decreased following treatment with Thiostrepton. Furthermore, a BALB/C nude mouse subcutaneous xenograft model was used to verify the function of FOXM1 in vivo. The present results demonstrated that FOXM1 inhibition significantly suppressed MDA-MB-231 cell tumorigenesis in vivo. Overall, the present results suggested that FOXM1 is a key gene that serves important roles in multiple biological processes in TNBC and that it may serve as a novel therapeutic target in TNBC.

Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression

A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple‐negative breast cancer

Forkhead Box C1 Boosts Triple‐negative Breast Cancer Metastasis Through Activating the Transcription of Chemokine Receptor‐4

FOXCUT Regulates the Malignant Phenotype of Triple-Negative Breast Cancer Via the Mir-337-3p/anp32e Axis

FOXC1-induced Non-Canonical WNT5A-MMP7 Signaling Regulates Invasiveness in Triple-Negative Breast Cancer

FOXC1 is a Critical Mediator of EGFR Function in Human Basal-like Breast Cancer

FOXC1: an emerging marker and therapeutic target for cancer

Forkhead Box C1 Promotes Colorectal Cancer Metastasis Through Transactivating ITGA7 and FGFR4 Expression

Exploring the Regulatory Role of FBXL19-AS1 in Triple-Negative Breast Cancer Through the Mir-378A-3p/otub2 Axis

Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression Via Mediating Hnrnpk/β-Catenin Complex.

Research progress on the forkhead box C1.

Data from LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer

Research Progress on the Regulatory Mechanisms of FOXC1 Expression in Cancers and Its Role in Drug Resistance.

Identification of FOXM1 As a Specific Marker for Triple‑negative Breast Cancer

EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers

Long Noncoding RNA Linc00339 Promotes Triple‐negative Breast Cancer Progression Through Mir‐377‐3p/hoxc6 Signaling Pathway

Loss of miR-634 contributes to the formation FOXA1-positive triple negative breast cancer subtype

FOXC1 in Cancer Development and Therapy: Deciphering Its Emerging and Divergent Roles

TGFB2-AS1 Inhibits Triple-Negative Breast Cancer Progression Via Interaction with SMARCA4 and Regulating Its Targetstgfb2andsox2

Binding blockade between TLN1 and integrin beta 1 represses triple-negative breast cancer

LINC01572 promotes triple‐negative breast cancer progression through EIF4A3‐mediated β‐catenin mRNA nuclear exportation